logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals poised for increased growth with new life changing products

Aequus Pharmaceuticals (CVE:AQS) CEO Doug Janzen joined Steve Darling in the Vancouver Proactive studio to give details about his company. Those detail include drugs already at market and others in the pipeline.

Janzen also shared information on one of those drugs, Aequus 1303 which is being developed to help pregnant women with nausea. Janzen also talked about their revenue streams and future outlook for the company. 

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.08 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $6.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Aequus Pharmaceuticals off to a great start in 2020 after...

Aequus Pharmaceuticals (CVE:AQS-OTCQB: AQSZF) Chairman and CEO Doug Janzen joined Steve Darling from Proactive Vancouver as the company released their 2019 financial numbers which saw Aequus set a revenue record in the 4th quarter. Janzen also discussed 2020 and where he sees the best...

on 4/5/20

2 min read